ORACEA® 40 mg* Capsules provide sustained anti-inflammatory effect with low plasma variability1,2
*30 mg immediate release & 10 mg delayed release beads
†Sixteen healthy subject in the ORACEA Capsules arm measured at 7 days; mean weight 75kg
Lead the way in limiting the risk of resistance
-
Every year in the United States 2 million people are infected with bacteria that are resistant to antibiotics4
-
Doxycycline accounts for nearly 1 out of 3 tetracycline prescriptions—the most commonly prescribed antibiotics5
-
Microbial resistance occurred in 7 days with doxycycline 100 mg/day3
-
Non-antibiotic dose ORACEA Capsules remained below the antimicrobial threshold6,7
-
There are no clinical studies to demonstrate additional anti-inflammatory effects of Doxycycline above 40 mg in rosacea patients